XML 116 R75.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreement - Additional Information (Details) - License and Collaboration Agreement - Astellas Pharma LLC - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 31, 2019
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Payments received under collaboration agreement $ 80,000          
Agreement termination notice period 60 days          
Right to terminate agreement if breach remains uncured 90 days          
Right to terminate agreement incase of nonpayment 45 days          
Transaction price allocated to single combined performance obligation       $ 80,000    
Upfront fee recognized as revenue $ 80,000          
joint cost   $ 14 $ 193   $ 392 $ 885
Phase 2b Clinical Trial | Europe            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized potential development milestone payments to receive 65,000          
Phase 2b Clinical Trial | Asia            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized potential development milestone payments to receive 25,000          
Phase 3 Clinical Trial | Europe            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized potential development milestone payments to receive 100,000          
Phase 3 Clinical Trial | Asia            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized potential development milestone payments to receive 40,000          
Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue recognized potential development milestone payments to receive 230,000          
Revenue recognized commercialization milestone payments to receive 315,000          
Potential commercial milestone payments eligible to receive upon successful commercialization $ 315,000